Bristol-Myers Squibb is recalling 8 lots of its highly popular anti-clotting drug Coumadin because the quantity of the active ingredient may vary. The recall affects more than 140,000 lots of 1 mg tablets of the anti-clotting drug. While there have been no reports of problems associated with the recall, variations in Coumadin may have serious consequences for patients taking Coumadin after surgical procedures. Those whose tablets contain too little of the active ingredient may be subject to an increased risk of blood clots while those whose tablets contain too much may bleed excessively.
The tablets subject to the recall have expiration dates between June 2011 and November 2012.
Latest posts by Jared Green (see all)
- Factors Impacting Maternal Health During Hospital Births - August 1, 2019
- New Hampshire Should Adopt a Safe Patient Ratio Statute - June 5, 2018
- Delays in Discharge Summaries Associated with HigherRate of Readmissions, Studies Show - February 7, 2018